Canaccord Genuity Maintains Buy on Cartesian Therapeutics, Raises Price Target to $43
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst John Newman maintains a Buy rating on Cartesian Therapeutics (NASDAQ:RNAC) and raises the price target from $38 to $43.
July 03, 2024 | 2:24 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Canaccord Genuity analyst John Newman maintains a Buy rating on Cartesian Therapeutics and raises the price target from $38 to $43.
The raised price target and maintained Buy rating from a reputable analyst can positively influence investor sentiment and potentially drive the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100